Physician

Shan R Fairbanks, D.O.

According to 2025 Medicare claims, Shan Fairbanks, D.O. (NPI: 1003202847) practices family practice in the Blacksburg-Christiansburg-Radford, VA market, with the plurality of this provider's patient population coming from Pulaski, VA. This provider's primary affiliated billing organization is CARILION HEALTHCARE CORPORATION (NPI: 1447206370; TIN: 540506332) and primary practice location at 24084-3211. Fairbanks is affiliated with the Doctors Connected (ACO ID: A4949), participating under the MSSP model.

Fairbanks' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 416 traditional Medicare patients, billed 4,539 HCPCS/CPT codes, and received $154,256 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 12,021 prescription claims across 718 beneficiaries totaling $804,410 in drug costs, led by Eliquis (Apixaban). DME data shows 137 claims. Open Payments data shows 1 records totaling $20. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,355 to $154,256. Similarly, Part D prescription costs have risen steadily, from $2,745 to $804,410. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $858 to $28,207.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	49	171	$4,355
2019	55	211	$4,500
2020	277	2,895	$97,378
2021	434	2,320	$95,041
2022	316	2,307	$97,085
2023	343	2,876	$119,037
2024	416	4,539	$154,256

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	28	79	$2,745
2017	53	487	$23,110
2018	91	847	$44,180
2019	114	779	$56,688
2020	139	247	$15,116
2021	469	2,328	$152,840
2022	508	6,250	$455,600
2023	589	7,813	$686,501
2024	718	12,021	$804,410

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	43	$388
2023	12	64	$1,648
2024	19	137	$16,121

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	201	201	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	351	830	$79
80061	Blood test, lipids (cholesterol and triglycerides)	185	260	$13
36415	Insertion of needle into vein for collection of blood sample	320	627	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	287	483	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	140	8,950	$166,195
Ozempic	Semaglutide	70	2,632	$81,048
Januvia	Sitagliptin Phosphate	38	2,580	$47,669
Jardiance	Empagliflozin	33	1,964	$38,861
Trulicity	Dulaglutide	38	1,138	$38,178

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	14	$10,685
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	14	$1,979
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	17	$1,670
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	14	$758
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	22	$569

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$20	Boston Scientific Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shan R. Fairbanks, D.O.?

Tedicare shows public-source Medicare data for Shan R. Fairbanks, D.O. (NPI 1003202847), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shan R. Fairbanks, D.O. have ACO affiliation data?

Shan R. Fairbanks, D.O. is shown with ACO affiliation data for Doctors Connected (MSSP, ACO ID A4949).

What billing organization is linked to Shan R. Fairbanks, D.O.?

Shan R. Fairbanks, D.O. is linked to CARILION HEALTHCARE CORPORATION (billing NPI 1447206370) in the available physician profile data.

Does Shan R. Fairbanks, D.O. have Open Payments data?

Shan R. Fairbanks, D.O. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.